Express Pharma

JANUARY 5, 2025

The Union Ministry of Health and Family Welfare revised the date of the implementation of the revised Schedule M of the Drugs and Cosmetics Act allowing pharma MSMEs an additional 12 months to comply, extending the date to December 31, 2025. To avail of this extension, pharma companies with a turnover of less than 250 crores must file an application with the Central Licensing Authority with details of their upgradation plan.

94

94

Med Ed 101

JANUARY 5, 2025

I’ve had some wonderful guest posts in the past and I couldn’t help but notice this awesome post on LinkedIn from a fellow pharmacist! April Oliveros is the author of this quick hitter on “Does Every Patient On Anticoagulation Need a PPI?” You can connect and follow her on LinkedIn right here. As clinical pharmacists, […] The post Does Every Patient On Anticoagulation Need a PPI?

52

52

Express Pharma

JANUARY 5, 2025

Addressing the 40th Foundation Day of the Department of Scientific and Industrial Research at Dr Ambedkar International Centre here, Union Minister Dr Jitendra Singh, Minister of State (Independent Charge) for Science and Technology, Earth Sciences (Independent Charge), MoS PMO, DoPT Personnel, Public Grievances and Pensions, Atomic Energy, Space, announced the indigenously developed drug Paracetamol, commonly used in pain, fever etc, by the Council of Scientific and Industrial Research (CSIR) w

86

86

FDA Law Blog: Biosimilars

JANUARY 5, 2025

By Deborah L. Livornese As promised in the Fall Unified Regulatory Agenda, FDA issued the final rule to establish the pathway to obtain marketing approval of a nonprescription drug product with an additional condition for nonprescription use (ACNU) on December 26, 2024, before the end of the calendar year. 89 Fed. Reg. 105288 (Dec. 26, 2024). We described the 2022 proposed rule and the ten-plus year history leading up to its issuance in our blog post here.

Labelling 59

Labelling 59

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Communication

Pharmaceutical Technology

JANUARY 5, 2025

LR-19155 is under clinical development by LG Chem and currently in Phase I for Non-Small Cell Lung Cancer.

40

40

Pharmacy Times

JANUARY 5, 2025

Fiber-rich foods show improvements in health and reductions in chronic diseases, including obesity, by promoting weight management and enhancing the metabolism.

24

24

ID Stewardship

JANUARY 5, 2025

In this article we do a quick run down on IDstewardship for the end of 2024. Article Posted January 2025 It was welcomed that 2024 did not feel like an extension of the 2020 COVID-19 pandemic as 2021-2023 had. I think many of us working in the infectious diseases space were grateful not to be at the mercy of pandemic demands. 2024 was a slower year for IDstewardship in regards to content creation and online engagement, but that still meant a lot of great new things were released.

Communication 52

Communication 52

Pharmaceutical Technology

JANUARY 5, 2025

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Rheumatoid Arthritis.

40

40

Pharmacy Joe

JANUARY 5, 2025

In this episode, Ill discuss delayed QTc prolongation in overdose patients. Episode 989: How to Identify an ED Toxicology Patient at Risk of Delayed QTc Prolongation Subscribe on iTunes , Android , or Stitcher Patients who present to the ED with acute drug overdose and a QTc above 500 msec are known to have an increased risk of adverse cardiac event and are therefore proactively monitored for this development.

Hospitals 97

Hospitals Inpatient 97

Pharmaceutical Technology

JANUARY 5, 2025

HLC-001 is under clinical development by Human Life CORD Japan and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

40

40

Advertisement

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

Pharmaceutical Technology

JANUARY 5, 2025

CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

NMDA Regulator is under clinical development by Boehringer Ingelheim International and currently in Phase I for Unspecified Central Nervous System Disorders.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

Paclitaxel is under clinical development by InnoUp Farma and currently in Phase I for Solid Tumor.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

Fosigotifator is under clinical development by Calico Life Sciences and currently in Phase II for Unspecified Central Nervous System Disorders.

40

40

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

Pharmaceutical Technology

JANUARY 5, 2025

Coronavirus Disease 2019 (COVID-19) vaccine is under clinical development by China National Biotec Group and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Pneumonia.

Vaccines 40

Vaccines 40

Pharmaceutical Technology

JANUARY 5, 2025

BNT-325 is under clinical development by BioNTech and currently in Phase II for Malignant Mesothelioma.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

RG-6315 is under clinical development by Genentech USA and currently in Phase I for Systemic Sclerosis (Scleroderma).

40

40

Pharmaceutical Technology

JANUARY 5, 2025

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Refractory Acute Myeloid Leukemia.

Immunity 40

Immunity Immunization 40

Advertisement

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

Pharmaceutical Technology

JANUARY 5, 2025

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Relapsed Acute Myeloid Leukemia.

Immunity 40

Immunity Immunization 40

Pharmaceutical Technology

JANUARY 5, 2025

AKS-452 is under clinical development by Vakston and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

40

40

Pharmaceutical Technology

JANUARY 5, 2025

SY-001 is under clinical development by CellOrigin Technology (Hangzhou) and currently in Phase I for Pancreatic Cancer.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

(Ensifentrine + glycopyrrolate) is under clinical development by Verona Pharma and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD).

40

40

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmaceutical Technology

JANUARY 5, 2025

LY-4052031 is under clinical development by Eli Lilly and Co and currently in Phase I for Ovarian Cancer.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

LY-4052031 is under clinical development by Eli Lilly and Co and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).

40

40

Pharmaceutical Technology

JANUARY 5, 2025

GM-103 is under clinical development by Genemedicine and currently in Phase II for Metastatic Colorectal Cancer.

40

40

Pharmaceutical Technology

JANUARY 5, 2025

SB-207 is under clinical development by Pelthos Therapeutics and currently in Phase II for Genital Warts (Condylomata Acuminata).

40

40

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Pharmaceutical Technology

JANUARY 5, 2025

RG-6315 is under clinical development by Genentech USA and currently in Phase I for Systemic Sclerosis (Scleroderma).

40

40

Pharmaceutical Technology

JANUARY 5, 2025

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Refractory Acute Myeloid Leukemia.

Immunity 40

Immunity Immunization 40

Pharmaceutical Technology

JANUARY 5, 2025

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Relapsed Acute Myeloid Leukemia.

Immunity 40

Immunity Immunization 40

Pharmaceutical Technology

JANUARY 5, 2025

AKS-452 is under clinical development by Vakston and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

40

40

Pharmaceutical Technology

JANUARY 5, 2025

SY-001 is under clinical development by CellOrigin Technology (Hangzhou) and currently in Phase I for Pancreatic Cancer.

40

40